Study Evaluating Isovorin in Advanced/Recurrent Gastric Cancer

Summary

The purpose of the study is to verify non-inferiority of survival time between Isovorin/5-fluorouracil (1-LV/5FU) therapy and TS-1 therapy in patients with inoperable advanced or recurrent gastric cancer. Secondary endpoints include response rates, duration of responses, time to progression (TTP) safety and quality of life (QOL).

Timeline

Start

2002-05

Primary completion

2008-08

Completion

2008-08

Drugs

Indications